Table of Contents
FORT LAUDERDALE, Fla. — China-based health technology company Sinocare Group has finalized its acquisition of diabetes management specialist Nipro Diagnostics and renamed it Trividia Health.
Nipro said Thursday that Scott Verner, its chairman, president and chief executive officer, has been named president and CEO of Trividia and will be joined by key executives from Fort Lauderdale, Fla.-based Nipro’s current management team. The company is slated to remain based in the United States.
“Our company has experienced strong growth as a result of our new product launch cadence and our investments in highly sophisticated manufacturing and distribution facilities in the United States. This is an exciting next chapter for our combined company,” Verner said in a statement. “I’m proud to have led the company through many changes in the public and private markets. I look forward to maximizing the global potential of our portfolio of solutions for patients, health care providers and our customers.”
A leading developer, manufacturer and marketer of advanced performance products for people with diabetes, Nipro products are sold under TRUE and store-brand labels. The company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for retail pharmacies, distributors and mail service providers.
Sinocare Group said Nipro’s new name, Trividia Health, reflects the company’s new trajectory and represents the values, vision and market of the global enterprise. “TRI” honors Sinocare’s three commitments to customers, employees and shareholders; “VI” stands for the commitment to patient victory over diabetes and other health challenges; and “DIA” refers to the company’s core diabetes foundation, according to the company. “HEALTH” was added to the name to signal the company’s new focus on developing integrated health solutions beyond diabetes.
“Like Sinocare, Nipro Diagnostics has the long-term vision of being a leading global health and wellness company that offers innovative, high-value solutions so patients can live healthier lives,” stated Sinocare chairman and CEO Shaobo Li. “We have a great deal of respect for what the management team and employees have accomplished at Nipro Diagnostics, and we are confident in their ability to accelerate our shared vision. Joined together, our proven portfolio of products and services, our combined future direction and our strong confidence in the people who design, manufacture and sell our products and services, will be vital to attaining our shared goals.”
Sinocare Group encompasses Sinocare Inc., Sinocare Jianheng Diabetes Hospita, and its affiliates. Sinocare Inc., headquartered in Changsha, China, is a provider of of biosensor technology, promoting diabetic self-management by using blood glucose monitoring systems, providing total diabetes services and solutions in China.
